Disseminated intravascular coagulation (Q56172333)

Nature Reviews Disease Primers

Europe PubMed Central

title

Disseminated intravascular coagulation (English)

0 references

2

Marcel Levi

0 references

author name string

Satoshi Gando

series ordinal

1

0 references

Cheng-Hock Toh

series ordinal

3

0 references

publication date

2 June 2016

0 references

published in

0 references

volume

2

0 references

page(s)

16037

0 references

cites work

Pathophysiology, clinical manifestations and therapy of consumption-coagulopathy (“Verbrauchskoagulopathie”)

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Natural history of disseminated intravascular coagulation diagnosed based on the newly established diagnostic criteria for critically ill patients: results of a multicenter, prospective survey.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

The recent time trend of outcomes of disseminated intravascular coagulation in Japan: an observational study based on a national administrative database

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Epidemiology of critical care syndromes, organ failures, and life-support interventions in a suburban US community

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Trends in the incidence and outcomes of disseminated intravascular coagulation in critically ill patients (2004-2010): a population-based study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Epidemiology of severe sepsis in Japanese intensive care units: a prospective multicenter study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

A multicenter, prospective validation study of the Japanese Association for Acute Medicine disseminated intravascular coagulation scoring system in patients with severe sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Application of the Japanese Association for Acute Medicine disseminated intravascular coagulation diagnostic criteria for patients at an early phase of trauma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Hemostasis during the early stages of trauma: comparison with disseminated intravascular coagulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Acute disseminated intravascular coagulation in obstetrics: a tertiary centre population review (1980 to 2009).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Innate immunity and coagulation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Thrombosis as an intravascular effector of innate immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Bidirectional relation between inflammation and coagulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Vascular bed-specific hemostasis: role of endothelium in sepsis pathogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Cancer Tissue Procoagulant Mechanisms and the Hypercoagulable State of Patients with Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Pathogenesis and management of peripartum coagulopathic calamities (disseminated intravascular coagulation and amniotic fluid embolism).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Rapid evaluation of fibrinogen levels using the CG02N whole blood coagulation analyzer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Coagulation and cancer: biological and clinical aspects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Microparticles are new biomarkers of septic shock-induced disseminated intravascular coagulopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Inflammation and coagulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Blood-borne tissue factor: another view of thrombosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

New fundamentals in hemostasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Role of inflammatory mediators in thrombogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Inflammation-associated ADAMTS13 deficiency promotes formation of ultra-large von Willebrand factor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Systemic infections mimicking thrombotic thrombocytopenic purpura

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

The regulation of natural anticoagulant pathways.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Inflammation and the activated protein C anticoagulant pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Endothelial cell protein C receptor plays an important role in protein C activation in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Coagulation in patients with severe sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiologic role for EPI as a natural anticoagulant

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

A short contemporary history of disseminated intravascular coagulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Plasminogen activator and plasminogen activator inhibitor I release during experimental endotoxaemia in chimpanzees: effect of interventions in the cytokine and coagulation cascades.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Fibrinolysis in disseminated intravascular coagulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Interleukin-1 Blockade Attenuates Mediator Release and Dysregulation of the Hemostatic Mechanism During Human Sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Thrombin signalling and protease-activated receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Extracellular histones promote thrombin generation through platelet-dependent mechanisms: involvement of platelet TLR2 and TLR4

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Neutrophil extracellular trap (NET) impact on deep vein thrombosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Neutrophil extracellular traps kill bacteria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Neutrophil extracellular traps: is immunity the second function of chromatin?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Extracellular DNA traps promote thrombosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Combination of antithrombin and recombinant thrombomodulin modulates neutrophil cell-death and decreases circulating DAMPs levels in endotoxemic rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Syndecan-4-dependent signaling in the inhibition of endotoxin-induced endothelial adherence of neutrophils by antithrombin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

New mechanisms for vascular control of inflammation mediated by natural anticoagulant proteins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Aggravation of endotoxin-induced disseminated intravascular coagulation and cytokine activation in heterozygous protein-C-deficient mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis: a 5-year overview

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Modified score for disseminated intravascular coagulation in the critically ill.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Diagnosis and prognosis of overt disseminated intravascular coagulation in a general hospital -- meaning of the ISTH score system, fibrin monomers, and lipoprotein-C-reactive protein complex formation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Disseminated intravascular coagulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Disseminated intravascular coagulation: old disease, new hope

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Current consideration and management of disseminated intravascular coagulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Regulation of the protein C anticoagulant and antiinflammatory pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Thrombin stimulates tissue plasminogen activator release from cultured human endothelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Thrombin induction of plasminogen activator-inhibitor in cultured human endothelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Laboratory evidence of disseminated intravascular coagulation is associated with a fatal outcome in children with cerebral malaria despite an absence of clinically evident thrombosis or bleeding

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Loss of endothelial protein C receptors links coagulation and inflammation to parasite sequestration in cerebral malaria in African children

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Severe malaria is associated with parasite binding to endothelial protein C receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

The cytoprotective protein C pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Differentiating disseminated intravascular coagulation (DIC) with the fibrinolytic phenotype from coagulopathy of trauma and acute coagulopathy of trauma-shock (COT/ACOTS).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Trauma, shock, and disseminated intravascular coagulation: lessons from the classical literature

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

A prospective study of venous thromboembolism after major trauma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

The production and availability of tissue thromboplastin in cellular populations of whole blood exposed to various concentrations of endotoxin. An assay for detection of endotoxin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Microparticle-associated tissue factor activity correlates with plasma levels of bacterial lipopolysaccharides in meningococcal septic shock

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

A combination of factor Xa and phosphatidylcholine-phosphatidylserine vesicles bypasses factor VIII in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Histone H4 promotes prothrombin autoactivation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Vascular ischaemia and reperfusion injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

P2X1 expressed on polymorphonuclear neutrophils and platelets is required for thrombosis in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Circulating histones are mediators of trauma-associated lung injury.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Circulating Histones Are Major Mediators of Cardiac Injury in Patients With Sepsis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Extracellular histones are mediators of death through TLR2 and TLR4 in mouse fatal liver injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Extracellular histones are major mediators of death in sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Recombinant thrombomodulin protects mice against histone-induced lethal thromboembolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Circulating Histone Concentrations Differentially Affect the Predominance of Left or Right Ventricular Dysfunction in Critical Illness

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Histones from dying renal cells aggravate kidney injury via TLR2 and TLR4.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Histones induce rapid and profound thrombocytopenia in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Mechanical stability and fibrinolytic resistance of clots containing fibrin, DNA, and histones.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Circulating levels of DNA-histone complex and dsDNA are independent prognostic factors of disseminated intravascular coagulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Dynamic evolution of coagulopathy in the first day of severe sepsis: relationship with mortality and organ failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Point of care coagulation tests in critically ill patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

A critical appraisal of point-of-care coagulation testing in critically ill patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Severe sepsis, coagulation, and fibrinolysis: dead end or one way?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Thrombin generation capacity of prothrombin complex concentrate in an in vitro dilutional model.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Prothrombin overload causes thromboembolic complications in prothrombin complex concentrates: in vitro and in vivo evidence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Increasing concentrations of prothrombin complex concentrate induce disseminated intravascular coagulation in a pig model of coagulopathy with blunt liver injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Endogenous thrombin potential following hemostatic therapy with 4-factor prothrombin complex concentrate: a 7-day observational study of trauma patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Unfractioned heparin for treatment of sepsis: A randomized clinical trial (The HETRASE Study)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Clinical evaluation of low-molecular-weight heparin (FR-860) on disseminated intravascular coagulation (DIC)--a multicenter co-operative double-blind trial in comparison with heparin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

A cell-based model of hemostasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

The role of natural anticoagulants in the pathogenesis and management of systemic activation of coagulation and inflammation in critically ill patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Drotrecogin alfa (activated) in adults with septic shock.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

A comparative double-blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

A systematic review of antithrombin concentrate use in patients with disseminated intravascular coagulation of severe sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: a secondary survey

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Antithrombin and mortality in severe pneumonia patients with sepsis-associated disseminated intravascular coagulation: an observational nationwide study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Supplemental dose of antithrombin use in disseminated intravascular coagulation patients after abdominal sepsis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Recombinant human soluble thrombomodulin and mortality in severe pneumonia patients with sepsis-associated disseminated intravascular coagulation: an observational nationwide study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Recombinant human soluble thrombomodulin in severe sepsis: a systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Benefit profile of recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Classifying types of disseminated intravascular coagulation: clinical and animal models

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Annexin II and bleeding in acute promyelocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

All-trans retinoic acid (ATRA) and tranexamic acid: a potentially fatal combination in acute promyelocytic leukaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Haemostatic problems in acute promyelocytic leukaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Regulation of Weibel-Palade body exocytosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Tranexamic acid for trauma – Authors' reply

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Effect of consent rituals on mortality in emergency care research

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Applying results from clinical trials: tranexamic acid in trauma patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Disseminated intravascular coagulation with a fibrinolytic phenotype at an early phase of trauma predicts mortality

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Systemic versus localized coagulation activation contributing to organ failure in critically ill patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Vascular-bed--specific hemostasis and hypercoagulable states

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

Importance of hemostatic gene polymorphisms for susceptibility to and outcome of severe sepsis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37

4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2016.37